ArticleTheranostics2018
Cyclin D1-mediated microRNA expression signature predicts breast cancer outcome.
Open access · goldAbstract read
In one paragraph
Article in Theranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 40 citations in OpenAlex.
- Research and development prospects of TRIM65.Journal of cancer research and clinical oncology · 2025Review
- Article
- The landscape of exosomal non-coding RNAs in breast cancer drug resistance, focusing on underlying molecular mechanisms.Frontiers in pharmacology · 2023Review
- The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance.Cancers · 2022Review
- Impact of circulating miRNA-373 on breast cancer diagnosis through targeting VEGF and cyclin D1 genes.Journal, genetic engineering & biotechnology · 2021Article
- Leronlimab, a humanized monoclonal antibody to CCR5, blocks breast cancer cellular metastasis and enhances cell death induced by DNA damaging chemotherapy.Breast cancer research : BCR · 2021Article
- piRNA-823 Is Involved in Cancer Stem Cell Regulation Through Altering DNA Methylation in Association With Luminal Breast Cancer.Frontiers in cell and developmental biology · 2021Article
- Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors.Frontiers in oncology · 2021Review
- Review
- Article
- Remodelling of the bone marrow microenvironment by stromal hyaluronan modulates the malignancy of breast cancer cells.Cell communication and signaling : CCS · 2020Article
- Relationships of hepatitis B virus infection with clinicopathological features in breast cancer and survival outcomes in central China.Translational cancer research · 2020Article
- The network of non-coding RNAs and their molecular targets in breast cancer.Molecular cancer · 2020Review
- Timeless-Stimulated miR-5188-FOXO1/β-Catenin-c-Jun Feedback Loop Promotes Stemness via Ubiquitination of β-Catenin in Breast Cancer.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- UCH-L1-mediated Down-regulation of Estrogen Receptor α Contributes to Insensitivity to Endocrine Therapy for Breast Cancer.Theranostics · 2020Article
- Theranostic application ofTheranostics · 2020Article
- miR-193a-5p promotes pancreatic cancer cell metastasis through SRSF6-mediated alternative splicing of OGDHL and ECM1.American journal of cancer research · 2020Article
- Recent advances with cyclin-dependent kinase inhibitors: therapeutic agents for breast cancer and their role in immuno-oncology.Expert review of anticancer therapy · 2019Review
- TGM2 interference regulates the angiogenesis and apoptosis of colorectal cancer via Wnt/β-catenin pathway.Cell cycle (Georgetown, Tex.) · 2019Article
- Bioinformatics analysis of dysregulated microRNAs in exosomes from docetaxel-resistant and parental human breast cancer cells.Cancer management and research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 3 countries.
Guangxue WangResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Michael GormleyDepartment of Cancer Biology, Thomas Jefferson University, 233 South 10 th St. Philadelphia PA 19107.
Jing QiaoResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Qian ZhaoResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Min WangPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center and Lankenau Institute for Medical Research, 100 East Lancaster Avenue, Suite, 222, Wynnewood, PA. 19096.
Gabriele Di SantePennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center and Lankenau Institute for Medical Research, 100 East Lancaster Avenue, Suite, 222, Wynnewood, PA. 19096.
Shengqiong DengResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Lin DongResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Tim PestellDepartment of Cancer Biology, Thomas Jefferson University, 233 South 10 th St. Philadelphia PA 19107.
Xiaoming JuDepartment of Cancer Biology, Thomas Jefferson University, 233 South 10 th St. Philadelphia PA 19107.
Mathew C CasimiroPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center and Lankenau Institute for Medical Research, 100 East Lancaster Avenue, Suite, 222, Wynnewood, PA. 19096.
Sankar AddyaDepartment of Cancer Biology, Thomas Jefferson University, 233 South 10 th St. Philadelphia PA 19107.
Adam ErtelDepartment of Cancer Biology, Thomas Jefferson University, 233 South 10 th St. Philadelphia PA 19107.
Ayden TozerenCenter for Integrated Bioinformatics, Drexel University, Philadelphia, PA 19104.
Qinchuan LiResearch Center for Translational Medicine, East Hospital, Tongji University School of Medicine, Shanghai 200120, China.
Zuoren YuPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center and Lankenau Institute for Medical Research, 100 East Lancaster Avenue, Suite, 222, Wynnewood, PA. 19096.
Richard G PestellPennsylvania Cancer and Regenerative Medicine Research Center, Baruch S. Blumberg Institute, Pennsylvania Biotechnology Center and Lankenau Institute for Medical Research, 100 East Lancaster Avenue, Suite, 222, Wynnewood, PA. 19096.
Shanghai East Hospital · CNThomas Jefferson University · USLankenau Institute for Medical Research · USDrexel University · USNanyang Technological University · SGSecond Military Medical University · CN
Funding
CYCLIN D1 FUNCTION IN PROSTATE CANCERR01CA086072 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2001 to 2013
$3.3MREGULATION OF CYCLIN D1 EXPRESSIONR01CA070896 · NCI · YESHIVA UNIVERSITY · PI PESTELL, RICHARD G · 2000 to 2010
$3.2MNCI NIH HHS R01 CA070896NCI NIH HHS R01 CA086072
Abstract
PubMed holds no abstract for this paper.
Indexed as
Gene Expression ProfilingGene Expression Regulation, NeoplasticAnimalsBreast NeoplasmsCyclin D1Estrogen Receptor alphaFemaleHumansMCF-7 CellsMiceMicroRNAsPrognosisTreatment OutcomeWnt Signaling PathwayCyclin D1Estrogen Receptor alphaMicroRNAsbreast cancercyclin D1miRNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.